These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9646853

  • 21. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R.
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [Abstract] [Full Text] [Related]

  • 22. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF, Liu MQ, Zhao Q.
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
    Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM.
    J Clin Oncol; 2006 May 20; 24(15):2376-85. PubMed ID: 16710036
    [Abstract] [Full Text] [Related]

  • 26. HER-2/neu oncogene expression in advanced breast cancer.
    Krogerus LA, Leivonen M.
    Cancer Detect Prev; 2001 May 20; 25(1):1-7. PubMed ID: 11270416
    [Abstract] [Full Text] [Related]

  • 27. Parathyroid hormone-related peptide (PTH-rp) in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis.
    Mylonas I, Makovitzky J, Shabani N, Richter DU, Jeschke U, Briese V, Friese K.
    Anticancer Res; 2005 May 20; 25(3A):1633-8. PubMed ID: 16033073
    [Abstract] [Full Text] [Related]

  • 28. [Amplification and expression of c-erbB2 oncogene in normal, hyperplastic, and malignant endometria].
    Lu Y, Czerwenka K, Heuss F.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov 20; 31(11):656-9. PubMed ID: 9387524
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 20; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.
    Hum Pathol; 2001 Dec 20; 32(12):1344-50. PubMed ID: 11774167
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Expression of replication-licensing factors MCM2 and MCM3 in normal, hyperplastic, and carcinomatous endometrium: correlation with expression of Ki-67 and estrogen and progesterone receptors.
    Kato K, Toki T, Shimizu M, Shiozawa T, Fujii S, Nikaido T, Konishi I.
    Int J Gynecol Pathol; 2003 Oct 20; 22(4):334-40. PubMed ID: 14501812
    [Abstract] [Full Text] [Related]

  • 37. Production of activin A in hyperplasia and adenocarcinoma of the human endometrium.
    Otani T, Minami S, Yamoto M, Umesaki N.
    Gynecol Oncol; 2001 Oct 20; 83(1):31-8. PubMed ID: 11585411
    [Abstract] [Full Text] [Related]

  • 38. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct 20; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 39. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
    Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT.
    Cancer Res; 2002 Jul 01; 62(13):3702-10. PubMed ID: 12097278
    [Abstract] [Full Text] [Related]

  • 40. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
    Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P.
    Cancer Res; 1990 Jul 01; 50(13):4087-91. PubMed ID: 1972347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.